Zobrazeno 1 - 10
of 412
pro vyhledávání: '"Bimekizumab"'
Autor:
Richard B. Warren, Kerry Donnelly, Sandeep Kiri, Vanessa Taieb, Mahmoud Slim, Kyle Fahrbach, Binod Neupane, Marissa Betts, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3133-3147 (2024)
Abstract Introduction Biologic treatments have made complete skin clearance in moderate to severe plaque psoriasis a real possibility. Although clinical trials demonstrated the superiority of bimekizumab over secukinumab, adalimumab, and ustekinumab,
Externí odkaz:
https://doaj.org/article/1b8b5aa9d0874f258cc203e0740e4093
Autor:
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili
Externí odkaz:
https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1413-1423 (2024)
Abstract Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriat
Externí odkaz:
https://doaj.org/article/4262254099cb40d39645fcfe05396997
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1403-1412 (2024)
Abstract Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis fact
Externí odkaz:
https://doaj.org/article/ce35de981e1147979941d6203e2e5191
Autor:
Zabotti A, Cabas N, Giovannini I, Guella S, Cereser L, Zuiani C, Stinco G, Quartuccio L, Errichetti E
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1553-1556 (2024)
Alen Zabotti,1 Nicola Cabas,1 Ivan Giovannini,1 Silvia Guella,1 Lorenzo Cereser,2 Chiara Zuiani,2 Giuseppe Stinco,3 Luca Quartuccio,1 Enzo Errichetti3 1Department of Medical and Biological Sciences, Rheumatology Institute, Azienda sanitaria universit
Externí odkaz:
https://doaj.org/article/678a648f59444c66a0bab1c33f965644
Autor:
Walter P. Maksymowych, Howard Thom, Michael F. Mørup, Vanessa Taieb, Damon Willems, Nikos Lyris, Karl Gaffney
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1023-1041 (2024)
Abstract Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis
Externí odkaz:
https://doaj.org/article/4b878f98b5e34d09a94b0e709d45235c
Autor:
Andrea Pagliara, Federico Bardazzi, Lidia Sacchelli, Federica Filippi, Camilla Loi, Bianca Maria Piraccini, Giacomo Clarizio
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 4 (2024)
Externí odkaz:
https://doaj.org/article/56b0827ef43e4e5a90a274de5060ec13
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/7d26cfef736148cb8d21e50168898a29
Autor:
Nicoletta Bernardini, Annunziata Dattola, Giacomo Caldarola, Diego Orsini, Chiara Assorgi, Alessandra D’Amore, Giulia Maretti, Antonio Giovanni Richetta, Ersilia Tolino, Nevena Skroza, Concetta Potenza
Publikováno v:
Drugs in Context, Vol 13, Pp 1-6 (2024)
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have
Externí odkaz:
https://doaj.org/article/d24f93036ce34a7ab8c5f3805c270115
Autor:
Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 829-839 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic
Externí odkaz:
https://doaj.org/article/160b6ba0575d44a484ca18255390de4e